RPRX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
690.1M
+2.4%
674.1M
+6.9%
630.6M
+1.4%
622.0M
+2.1%
609.3M
Cost of Revenue
0
0
0
0
0
Gross Profit
690.1M
+2.4%
674.1M
+6.9%
630.6M
+1.4%
622.0M
+2.1%
609.3M
Operating Expenses
279.3M
-48.4%
541.0M
+701.1%
67.5M
-71.1%
233.6M
+28.3%
182.1M
R&D
63.2M
-35.5%
97.9M
+145.9%
39.8M
-21.2%
50.5M
+0.0%
50.5M
SG&A
150.1M
-7.3%
161.9M
+1.5%
159.5M
-2.9%
164.3M
+38.4%
118.7M
Operating Income
410.8M
+208.6%
133.1M
-76.4%
563.0M
+45.0%
388.4M
-9.1%
427.2M
EBITDA
472.9M
+255.2%
133.1M
-69.4%
435.0M
-38.5%
707.3M
+61.0%
439.3M
Net Income
266.6M
+227.2%
81.5M
-82.6%
468.3M
+31.6%
355.9M
-19.1%
440.2M
EPS (Basic)
$0.32
+700.0%
$0.04
-94.0%
$0.67
+34.0%
$0.50
-24.2%
$0.66
EPS (Diluted)
$0.32
+700.0%
$0.04
-94.0%
$0.67
+76.3%
$0.38
-42.4%
$0.66
Shares (Diluted)
557.0M
+0.0%
556.9M
+0.0%
556.8M
-0.2%
557.8M
-0.3%
559.6M
Royalty Pharma (RPRX) — Financials